Aegis Study Shows Impact of InterACT Rx on Medication Management and Patient Care
Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical decision making, and improve patient outcomes.
Nashville, Tennessee (Oct. 9, 2018) - In a recently published study of 262 patients, there was a signifcant reduction in all-cause and painrelated outpatient visits and medication use between the pre- and post-index periods, including in the total number of prescriptions for opioid analgesics involved in.
The majority of drug–drug interactions detected (77.9%) at index were of moderate severity. The number of monthly all-cause and pain-related outpatient visits was reduced in the post-index period compared with the pre-index period (0.74–0.54 and 0.69–0.49, respectively). Associated costs were reduced from US$64.92 to US$51.20, and from US$62.42 to US$47.62, (p < 0.0001 for both) for all-cause and pain-related outpatient visits, respectively. Follow-up drug–drug interaction testing for 43 patients revealed that previously reported drug–drug interactions at the index test were no longer identifed in the subsequent test for 39.5% of patients.
Aegis Sciences Corporation offers a test (InterACT Rx™) that objectively and defnitively identifes substances known to interact with drug–drug interaction-prone medications commonly prescribed in the treatment of chronic pain and behavioral health disorders.
Click here for more information on InterACT RxTM
Click here to view the article abstract
Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs - Real World Outcomes has a broad scope, encompassing studies investigating drug utilisation, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses.
About Aegis Sciences Corporation
Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as healthcare providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information please visit http://www.aegislabs.com/.